Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
GLP-1 Albiglutide Review Time Extended
The FDA has extended the review time for GlaxoSmithKline’s (GSK) incretin mimetic once-weekly GLP-1 diabetes treatment albiglutide, delaying the deadline for delivering a verdict on the drug until April 15 next year.